Polyamine blockade promotes antitumor immunity

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Hayes, Candace S ^a   Burns, Mark R ^b   Gilmour, Susan K ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b Aminex Therapeutics Inc   (United States)

Author keywords

Difluoromethylornithine; Immunomodulation; Polyamines; Transport inhibitor; Tumor microenvironment

Indexed keywords

ADENOSINE; ARGINASE 1; ARGININE; EFLORNITHINE; INDOLEAMINE 2,3 DIOXYGENASE 1; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ORNITHINE DECARBOXYLASE; OXYGENASE; POLYAMINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ASSOCIATION; GRANULOCYTE; IMMUNOLOGICAL PROCEDURES; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; PHENOTYPE; POLYAMINE BLOCKER THERAPY; POLYAMINE DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84899067289     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27360     Document Type: Article

References (10)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi. org/10.1038/nrc3239.
2. Gottfried E, Kreutz M, Mackensen A. Tumor metabolism as modulator of immune response and tumor progression. Semin Cancer Biol 2012; 22:335-41; PMID:22414910; http://dx.doi.org/10.1016/j. semcancer.2012.02.009.
3. Soda K. The mechanisms by which polyamines accelerate tumor spread. J Exp Clin Cancer Res 2011; 30:95; PMID:21988863; http://dx.doi. org/10.1186/1756-9966-30-95.
4. Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004; 4:781-92; PMID:15510159; http://dx.doi. org/10.1038/nrc1454.
5. Hayes CS, Shicora, AC Keough, MP, Snook AE, Burns MR, Gilmour SK. Polyamine-Blocking Therapy Reverses Immunosuppression in the Tumor Microenvironment. Cancer Immunolgy Research; Forthcoming; DOI: 10.1158/2326-6066.
6. Hayes CS, Defeo K, Dang H, Trempus CS, Morris RJ, Gilmour SK. A prolonged and exaggerated wound response with elevated ODC activity mimics early tumor development. Carcinogenesis 2011; 32:1340-8; PMID:21730362; http://dx.doi.org/10.1093/carcin/bgr129.
7. Keough MP, Hayes CS, DeFeo K, Gilmour SK. Elevated epidermal ornithine decarboxylase activity suppresses contact hypersensitivity. J Invest Dermatol 2011; 131:158-66; PMID:20844550; http://dx.doi. org/10.1038/jid.2010.263.
8. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64:5839-49; PMID:15313928; http://dx.doi.org/10.1158/0008-5472.CAN-04-0465.
9. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005; 174:636-45; PMID:15634881.
10. Selamnia M, Mayeur C, Robert V, Blachier F. Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. Biochem Pharmacol 1998; 55:1241-5; PMID:9719479; http://dx.doi.org/10.1016/S0006-2952(97)00572-8.